We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
+5.05%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.58B
AUM Growth
+$636M
Cap. Flow
+$643M
Cap. Flow %
17.97%
Top 10 Hldgs %
40.4%
Holding
113
New
37
Increased
33
Reduced
14
Closed
23

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$210M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$166M
3
RGEN icon
Repligen
RGEN
+$118M
4
ARWR icon
Arrowhead Research
ARWR
+$87M
5
IMCR icon
Immunocore
IMCR
+$70.6M

Top Sells

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$191M
2
TERN
Terns Pharmaceuticals
TERN
+$144M
3
DXCM icon
DexCom
DXCM
+$84.6M
4
MRK icon
Merck
MRK
+$81.6M
5
TYRA icon
Tyra Biosciences
TYRA
+$76.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$38.9B
$231M 6.46%
2,375,000
+2,080,000
+705% +$210M
BMRN icon
2
BioMarin Pharmaceuticals
BMRN
$12.2B
$202M 5.65%
3,575,000
+575,000
+19% +$33.5M
ABVX
3
Abivax
ABVX
$10.7B
$167M 4.67%
1,500,000
-400,000
-21% -$47.3M
NBIX icon
4
Neurocrine Biosciences
NBIX
$18.1B
$165M 4.6%
+1,250,000
New +$166M
ARWR icon
5
Arrowhead Research
ARWR
$11.9B
$143M 3.99%
2,275,000
+1,375,000
+153% +$87M
ELVN icon
6
Enliven Therapeutics
ELVN
$3.74B
$127M 3.56%
3,250,000
-580,000
-15% -$16.1M
RGEN icon
7
Repligen
RGEN
$8.51B
$109M 3.05%
925,000
+842,000
+1,014% +$118M
BCAX
8
Bicara Therapeutics
BCAX
$1.78B
$108M 3.02%
5,425,000
+1,850,000
+52% +$31.8M
NRIX icon
9
Nurix Therapeutics
NRIX
$2.35B
$101M 2.82%
6,500,000
+1,810,000
+39% +$30M
APGE icon
10
Apogee Therapeutics
APGE
$10.1B
$92.6M 2.59%
1,100,000
+550,000
+100% +$39.9M
ASND icon
11
Ascendis Pharma A/S
ASND
$16.3B
$85.8M 2.4%
375,000
+200,000
+114% +$44.8M
IMCR icon
12
Immunocore
IMCR
$1.7B
$83.4M 2.33%
2,766,868
+2,181,868
+373% +$70.6M
TSHA icon
13
Taysha Gene Therapies
TSHA
$1.55B
$80.5M 2.25%
18,000,000
+4,250,000
+31% +$19.8M
DYN icon
14
Dyne Therapeutics
DYN
$4.25B
$72.5M 2.03%
4,000,000
+3,880,000
+3,233% +$66.9M
SNY icon
15
Sanofi
SNY
$109B
$67.5M 1.89%
+1,400,000
New +$65.3M
BCRX icon
16
BioCryst Pharmaceuticals
BCRX
$2.43B
$66.9M 1.87%
7,025,000
+4,775,000
+212% +$37.1M
SRRK icon
17
Scholar Rock
SRRK
$5.73B
$65.1M 1.82%
1,324,422
+624,422
+89% +$28M
IMTX icon
18
Immatics
IMTX
$1.13B
$60.8M 1.7%
6,175,000
+50,000
+0.8% +$490K
BMY icon
19
Bristol-Myers Squibb
BMY
$133B
$60.6M 1.7%
1,000,000
+750,000
+300% +$43.7M
ALC icon
20
Alcon
ALC
$34B
$60.3M 1.69%
800,000
-305,000
-28% -$24.3M
GLUE icon
21
Monte Rosa Therapeutics
GLUE
$1.84B
$59.3M 1.66%
3,603,465
+2,828,465
+365% +$54.1M
VERA icon
22
Vera Therapeutics
VERA
$2.36B
$55M 1.54%
1,368,159
+818,159
+149% +$35.2M
TERN
23
DELISTED
Terns Pharmaceuticals
TERN
$52.7M 1.47%
1,000,000
-3,500,000
-78% -$144M
GMED icon
24
Globus Medical
GMED
$10.9B
$52.6M 1.47%
610,520
-664,480
-52% -$59.6M
BSX icon
25
Boston Scientific
BSX
$69.9B
$50.2M 1.4%
+800,000
New +$64M
1
2 3 4 5

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
WB
WesBanco Bank Wheeling, West Virginia $3.61B AUM 24.09% 1-Year Est. Return

Vestal Point Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Vestal Point Capital held 113 positions worth $3.58B, up 22% from $2.94B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Vestal Point Capital deployed $643M of net new capital in Q1 2026, opening 37 new positions and adding to 33 existing holdings. Its largest new stake was Neurocrine Biosciences: 1,250,000 shares worth $165M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 93% a quarter earlier.

On the sell side, the largest reduction was Terns Pharmaceuticals, an estimated $144M trimmed.

  • Vestal Point Capital's largest Q1 2026 buy was Neurocrine Biosciences: 1,250,000 shares worth $165M.
  • Vestal Point Capital added most to Revolution Medicines in Q1 2026, an estimated $210M increase.
  • Vestal Point Capital's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $144M.
  • Vestal Point Capital fully exited Arcellx in Q1 2026, selling an estimated $191M.
  • Vestal Point Capital's ten largest holdings make up 40% of its $3.58B portfolio in Q1 2026.
  • Vestal Point Capital opened 37 new positions and closed 23 in Q1 2026.
  • Vestal Point Capital's portfolio value rose 22% quarter-over-quarter to $3.58B.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.